Showing 123 results
-
Media Release /Ribociclib plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting NATALEE is the first and only positive Phase III…
-
Media Release /The Philippine Food and Drug Administration (FDA) has approved brolucizumab for the treatment of visual impairment due to diabetic macular edema (DME), a common microvascular complication in…
-
Media Release /The Alliance and Partnerships for Patient Innovation and Solutions (APPIS) platform will hold its third annual virtual Summit on March 20-21, 2023. Organized by Novartis and co-created by the…
-
Media Release /Chronic kidney disease (CKD) is among the leading causes of sickness and death in the Philippines. Latest estimates show that around 2.3 million Filipinos have CKD.3 The National Kidney and…
-
Media Release /Novartis continuously finds ways to help improve the quality of care for Filipino patients living with cancer, which is one of the leading causes of illness and death in the Philippines. In…
-
Media Release /To help reduce the heavy burden of cardiovascular diseases (CVDs), Novartis launched the Unblocked movement for heart health – an initiative co-created with external stakeholders in the healthcare…
-
Media Release /Novartis and the Novartis Foundation have been working with the Department of Health and other partners to eliminate leprosy for over 30 years. The Novartis Foundation focuses on influencing…
-
Media Release /Novartis Healthcare Philippines has been officially recognized by the Top Employers Institute as a Top Employer 2023 in the Philippines. To become recognized as a Top Employer, an organization…
-
Media Release /The ICanServe Foundation, City of Taguig, local healthcare software startup Dashlabs, and Novartis have launched the Circle of Life Data and Digital Infrastructure project to support the Ating…
-
Media Release /In a developing country like the Philippines, where healthcare delivery is mostly paid through patients' out-of-pocket expenses, the economic burden of heart failure (HF), especially…
